Cisco's next quarterly call, which will reflect our fiscal year 2025 third-quarter results, will be on Wednesday, May 14, ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

The Company's Board of Directors (the "Board”) approved payment of the $0.0075 per share per month dividend beginning in ...

Q2 2025 Earnings Call Transcript February 12, 2025 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.26, ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...

Iga Swiatek will look to extend her victorious run in Doha at Qatar Open 2025, where she will aspire to become the first four ...

Q2 2025 Earnings Call Transcript February 6, 2025 Operator: Good day, everyone, and welcome to Lumentum Holdings Second ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Greetings, and welcome to the Great Elm Group Fiscal 2025 Second Quarter Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Good morning, and welcome to the Conference Call for Tate & Lyle's Q3 Trading Statement. Your speakers today are Nick Hampton, Chief Executive; and Sarah Kuijlaars, Chief Financial Officer. I will now ...